KHAV Overview
- Year Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
6
KHAV General Information
Description
Developer of drug therapeutics designed to find cures and resistance for various diseases. The company specializes in providing vaccinations for diseases like bronchitis, metapneumovirus infection, and Gambero disease, enabling healthcare professionals to provide patients with cures for these diseases.
Contact Information
Website
www.khav.co.krCorporate Office
- 261-34, Sagab 1-gil, Seoun-myeon
- Anseong, Gyeonggi
- South Korea
Corporate Office
- 261-34, Sagab 1-gil, Seoun-myeon
- Anseong, Gyeonggi
- South Korea
KHAV Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC | 01-Jan-2021 | Completed | Generating Revenue | |||
| 1. Seed Round | 01-Jan-2020 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
KHAV Patents
KHAV Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025116613-A1 | Pharmaceutical composition for cancer treatment, comprising recombinant newcastle disease virus vectors | Inactive | 29-Nov-2023 | ||
| WO-2024128804-A1 | Sars-cov-2 virus vaccine | Inactive | 14-Dec-2022 | ||
| EP-4560014-A1 | Attenuated strain of avian infectious bronchitis virus and vaccine composition containing same | Pending | 22-Jul-2022 | ||
| EP-4560014-A4 | Attenuated strain of avian infectious bronchitis virus and vaccine composition containing same | Pending | 22-Jul-2022 | ||
| WO-2024019579-A1 | Attenuated strain of avian infectious bronchitis virus and vaccine composition containing same | Inactive | 22-Jul-2022 | A61P31/14 |
KHAV Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brick (South Korea) | Venture Capital | Minority | ||
| InterVest | Venture Capital | Minority | ||
| KG Zeroin | Corporation | Minority | ||
| Loftyrock Investment | Venture Capital | Minority | ||
| Simpac | Corporation | Minority |
KHAV FAQs
-
When was KHAV founded?
KHAV was founded in 2014.
-
Where is KHAV headquartered?
KHAV is headquartered in Anseong, South Korea.
-
What industry is KHAV in?
KHAV’s primary industry is Drug Discovery.
-
Is KHAV a private or public company?
KHAV is a Private company.
-
What is KHAV’s current revenue?
The current revenue for KHAV is .
-
Who are KHAV’s investors?
Brick (South Korea), InterVest, KG Zeroin, Loftyrock Investment, and Simpac are 5 of 6 investors who have invested in KHAV.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process